Summary In a series of 46 glioblastomas, 16 anaplastic astrocytomas and eight astrocytomas, all tumours retaining one or both alleles of CDKN2A (48 tumours) and CDKN2B (49 tumours) were subjected to sequence analysis (entire coding region and splice acceptor and donor sites). One glioblastoma with hemizygous deletion of CDKN2A showed a missense mutation in exon 2 (codon 83) that would result in the substitution of tyrosine for histidine in the protein. None of the tumours retaining alleles of CDKN2B showed mutations of this gene. Glioblastomas with retention of both alleles of CDKN2A (14 tumours) and CDKN2B (16 tumours) expressed transcripts for these genes. In contrast, 7/13 glioblastomas with hemizygous deletions of CDKN2A and 8/11 glioblastomas with hemizygous deletions of CDKN2B showed no or weak expression. Anaplastic astrocytomas and astrocytomas showed a considerable variation in the expression of both genes, regardless of whether they retained one or two copies of the genes. The methylation status of the 5' CpG island of the CDKN2A gene was studied in all 15 tumours retaining only one allele of CDKN2A as well as in the six tumours showing no significant expression of transcript despite their retaining both CDKN2A alleles. Three tumours (one of each malignancy grade studied) were found to have partially methylated the 5' CpG island of CDKN2A. It appears that in human astrocytic gliomas point mutations of the CDKN2A and CDKN2B genes are uncommon and hypermethylation of the 5' CpG region of CDKN2A does not appear to be a major mechanism for inhibiting transcription of this gene.
homozygous deletions of these genes in 19/46 glioblastomas, 3/16 anaplastic astrocytomas and in 0/8 astrocytomas (Schmidt et al, 1994) . In addition, CDK4 gene amplification with overexpression was found in approximately 15% of these tumours (Reifenberger et al, 1994) and was seen almost exclusively in tumours without deletions of CDKN2A and CDKN2B. Thus, two different aberrations of the same pathway may lead to increased Cdk4/cyclinDl formation in astrocytic gliomas (Schmidt et al, 1994) .
Point mutations in CDKN2A have been shown in tumours retaining one allele, and in some cases have been shown to result in a protein unable to bind Cdk4. Tumours with such mutations of CDKN2A include pancreatic adenocarcinomas (Caldas et al, 1994) , oesophageal squamous cell carcinomas (Mori et al, 1994) , familial melanomas (Hussussian et al, 1994; Kamb et al, 1994b) , nonsmall-cell lung carcinomas (NSCLC) (Washimi et al, 1995) and single cases of gliomas (Ueki et al, 1994 (Ueki et al, , 1996 Li et al, 1995; Moulton et al, 1995) . Hypermethylation of the 5' CpG island of the CDKN2A gene has been reported as a mechanism inhibiting gene expression in some tumour cells (Gonzalez-Zulueta et al, 1995; Herman et al, 1995; Merlo et al, 1995; Otterson et al, 1995) . The CDKN2B gene has not been examined to the same extent.
In order to obtain further evidence that loss of a functional p16 and p15 protein is involved in the progression of astrocytic tumours, we studied our tumour series for point mutations of these genes. The transcript expression of these genes was also examined, and in the case of CDKN2A it was correlated with a study of the methylation of the CpG island in the 5' region of this gene. The findings show that mutations are infrequent and methylation does not appear to be a major mechanism inhibiting CDKN2A transcription in primary astrocytic tumours.
MATERIALS AND METHODS Tumour and control tissue, DNA and RNA extraction
The material consisted of 70 tumours including 46 glioblastomas (GB), 16 anaplastic astrocytomas (AA) and eight astrocytomas (A). All have been reported previously using the same tumour numbers (Schmidt et al, 1994) . DNA and RNA were extracted as described previously (Reifenberger et al, 1993) . In addition, non-neoplastic adult human brain tissue (cortex and white matter) (Schmidt et al, 1994) , exposed on Storage Phosphor Screens and analysed using a PhosphorImager as previously described (Schmidt et al, 1994) . This probe encompasses the SmaI site in exon 1, giving rise to the same band pattern on a SmaIlEcoRI blot as the exon 1 probe described by Merlo et al (1995) .
PCR-based methylation assay
Genomic DNA (80 ng) was either digested with 10 U (0.5 U ,tl-') of three methylation-sensitive enzymes (SmaI, HpaII and SacII) or placed in the appropriate buffer without enzyme (control), followed by ethanol precipitation. Aliquots of 20 ng of the digested and non-digested DNA were then amplified by PCR for 28 cycles (primers: 2F and 1108R; see Table 1 ). The results were confirmed by two independent DNA digestion and PCR reactions. As a control for template recovery after ethanol precipitation, a 
RESULTS
In a previous study, we have deletion mapped 9p evaluating 16 loci including the CDKN2A and CDKN2B genes in a series of 70 primary astrocytic gliomas (Ichimura et al, 1994; Schmidt et al, 1994) . Here, we have sequenced the coding region and splice sites of all retained alleles of these two genes in the same tumour series (see Table 2 ). Genomic sequences covering all coding sequences were amplified by PCR using the primers listed in Table 1 and the products submitted to cycle sequencing. Among the 48 tumours sequenced, one somatic missense mutation was demonstrated in exon 2 of CDKN2A in a glioblastoma (GB36) retaining one copy of CDKN2A (Figure 1 ). At position 287 of the reference sequence (see below), C was replaced by T, resulting in the substitution of histidine by tyrosine. The mutation was confirmed by repeating the PCR amplification and sequencing, and proven to be somatic by comparing it with the patient's white blood cell DNA. None of the 49 tumours sequenced for CDKN2B showed any mutations in the entire coding region or the splice acceptor and donor sequences.
We found consistent differences in the sequences from the reported CDKN2A sequence [GenBank, accession number L2721 1, ver.8 and intron sequences reported by Kamb et al (1994a) ] in the individual patient's normal white blood cell DNA. In the non-coding region of exon 1, bases 15, 19 and 22 read G whereas the reference sequence shows them as A. At position 27 of the reference sequence we found a C/T polymorphism in one tumour, which was heterozygous at this position. Two of the patients showed the threonine-alanine polymorphism at position 482 of the reference sequence, which has been described previously (Cairns et al, 1994; Spruck et al, 1994; Ueki et al, 1994) . In exon 3 of CDKN2A we confirmed the G/C polymorphism located in the 3' non-coding region at base 540 of the reference sequence, as described by Ueki et al (1994) .
We also found differences from the CDKN2B reference sequence [GenBank, accession number L36844, ver.2 and intron sequences reported by Kamb et al (1994a) ] in the coding sequence of exon 1 confirming the findings of Guan et al (1994) , who cloned the CDKN2B cDNA independently. These base changes alter the expected amino acid sequence from the reference sequence (between bases 385 and 390 three bases are missing, the amino acid sequence becoming Ser-Ala-Ala instead of Thr-Pro; and between bases 418 and 426 a rearrangement of the base sequence changes His-Ser-Trp to Gln-Leu-Leu). In intron 1 of CDKN2B we detected a C/A polymorphism 27 nucleotides upstream of exon 2.
As point mutations of the CDKN2A and CDKN2B genes do not appear to be a major mechanism for the loss of a functional protein we addressed the question of whether lowered or absent transcript expression could represent an alternative mechanism. Using RT-PCR we studied 63 tumours (no RNA was available in seven tumours). A summary of the results is given in Table 2 . As expected, tumours with homozygous deletions of CDKN2A and/or CDKN2B showed no product after RT-PCR. Only two tumours (GB 151, AA18) showed a detectable signal, which was interpreted as being derived from the normal cells in the tumour tissue. All glioblastomas that retained both alleles of CDKN2A and CDKN2B clearly expressed both genes. Among the glioblastomas that retained only one copy of these genes, 7/13 (CDKN2A) and 8/11 (CDKN2B) showed no or weak expression (Figure 2 ). The expression levels were generally similar for both genes. Among the anaplastic astrocytomas and astrocytomas, regardless of whether they retained one or two gene copies, expression of both CDKN2A and CDKN2B showed a heterogeneous pattern. All tumours with CDK4 amplification that retain one or both copies of CDKN2A and CDKN2B clearly expressed both genes. The mutated CDKN2A allele in GB36 was also strongly expressed. GB 14, which has a homozygous deletion of CDKN2A but retains one allele of CDKN2B, did not express CDKN2B.
In order to examine whether decreased expression of the CDKN2A gene is associated with hypermethylation of its 5' CpG island (Gonzalez-Zulueta et al, 1995; Herman et al, 1995; Otterson et al, 1995) , we assessed the methylation status of tumours by digesting DNA with methylation-sensitive restriction enzymes. Twenty-one tumours were analysed using EcoRIISmal digestion and Southern blotting ( Figure 3A-C) . These included 15 tumours with hemizygous deletions and six with low or absent expression of CDKN2A despite the retention of both alleles. No tumour showed complete methylation of all SmaI sites. Three tumours (GB7, A5 and AA13) revealed a pattern consistent with methylation of one or two SmaI sites in the region ( Figure  3A -C and Table 2 ). However, expression of CDKN2A was seen in GB7 whereas no expression was detected in A5. Both tumours showed an identical 0.9-kb band in addition to the expected bands from unmethylated restriction sites. AA13 showed a 3.3-kb band in addition to the normal pattern and expressed the transcript. The identity of the 0.9-kb and 3.3-kb fragments was confirmed by hybridizing the Southern blots with the 5' and 3' ends of the exon 1 probe digested with HpaII (see map in Figure 3A and B; data not shown). Other tumours, such as GB29 and GB34 showed no evidence of methylation yet GB29 expressed and GB34 did not express the CDKN2A transcript ( Figure 3C ). To confirm these results and to further characterize tumours with partial methylation of the 5' CpG island, one SmaI site [SmaI(2)], one Sacll site and two HpaII sites within exon 1 ( Figure 3A) were examined in a PCR-based methylation assay. No tumour showed clear evidence of methylation of the SmnaI and the HpaII restriction sites ( Figure  3D , HpaII data not shown). One tumour (AS) that had been shown GB28  GB21  GB69  GB1 50  GB2  GB40  GB4  GB1 7  GB1  GB1 6  GB45  GB38  GB6  GB22  GB1 51  GB1 4  GB36  GB24  GB5  GB34  GB23  GB144  GB41  GB8  GB39  GB7  GB30  GB25  GB29  GB26  GB37  GB90  GB1 42  GB1 3  GB1 1  GB1 54  GB1 0  GB1 2  GB1 5  GB44  GB27  GB1 05  GB1 2  2  2  2  2  2  2  2   2   2   2  2   2   2   1   1  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2 (GB14, GB1 50) , the 13 glioblastomas with hemizygous deletions (GB7-GB29), 2 of the 14 glioblastomas with retention of both alleles (GB26 which has CDK4 amplification and GB1 2 without CDK4 amplification) and the anaplastic astrocytoma (AA1 3) and astrocytoma (A5) that showed partial methylation of the CDKN2A gene (see also Figure 3 ). Figure  3A -C) also revealed methylation of the SacII site ( Figure 3D (Serrano et al, 1993 ). An identical mutation has been described in a pancreatic tumour retaining one allele (Caldas et al, 1994) . The protein resulting from this mutation showed only 8% of wild-type Cdk4 binding activity and could not inhibit Rb phosphorylation in an in vitro assay . No somatic mutations were found in the CDKN2B gene. Point mutations in CDKN2A and CDKN2B thus appear to be an infrequent event in astrocytic tumours. Several studies of the CDKN2A and CDKN2B genes in primary gliomas have been performed using single-strand conformation polymorphism (SSCP) or sequencing of parts of the coding sequences (Giani and Finocchiaro, 1994; Ueki et al, 1994 Ueki et al, , 1996 Li et al, 1995; Moulton et al, 1995; Sonoda et al, 1995) . In total, four point mutations have been reported, indicating a low frequency of point mutations in gliomas. In order to investigate alternative mechanisms that could result in the absence of a functional protein, we examined the methylation status of the CDKN2A 5' CpG island and studied the expression of the transcript. Hypermethylation of the 5' CpG island in the promoter region and exon 1 of CDKN2A has been reported to be correlated with transcriptional silencing (Gonzalez-Zulueta et al, 1995; Herman et al, 1995; Merlo et al, 1995; Otterson et 1995). Merlo et al (1995) showed that complete methylation of this region was associated with lack of CDKN2A expression in NSCLC, small-cell lung cancer and head and neck squamous-cell carcinoma cell lines. Partial demethylation by 5-deoxyazacytidine led to expression of the gene. Several primary tumours including gliomas also showed band patterns consistent with complete or partial methylation but expression data were not presented . Gonzalez-Zulueta et al (1995) examined the methylation status of CDKN2A and CDKN2B in primary transitional cell carcinomas of bladder (TCC) and colon cancer by a PCR-based methylation analysis and found a correlation between hypermethylation of CDKN2A exon 1 and lack of CDKN2A expression in TCC. In our series all the 15 tumours retaining one allele of CDKN2A showed variable expression levels. Two of these tumours (GB7 and AA13) showed restriction patterns consistent with partial methylation affecting one or two SmaI sites. However, both expressed the gene. This could be explained by the presence of two distinct tumour subpopulations, one of which has some methylation sites methylated in the CDKN2A 5' CpG region and does not express the transcript, the other having no methylation of this region and expressing the gene. These tumours show additional, strong bands consistent with unmethylated restriction sites ( Figure 3A -C). These bands are unlikely to be derived from normal cells as the normal cell population in these tumours was low as judged by microsatellite and Southern blot analyses as well as by histopathology of the tissue studied (data not shown). The presence of subpopulations in these tumour tissues makes correlation between methylation and expression status difficult. All astrocytomas retained both copies of CDKN2A but three of these tumours did not appear to express a transcript. (Serrano et al, 1993; Li et al, 1994; Parry et al, 1995) . A negative feedback loop between Rbl and p16 has been suggested . The tumours in our series that show strong expression of CDKN2A could be overexpressing the gene owing to inactivation of the RBI gene by deletion or mutation. This has been confirmed for some of these tumours in a parallel study in which we examined the status of the RBI gene in a large number of astrocytic tumours (Ichimura et al, 1996) . Furthermore, CDK4 overexpression could conceivably result in Rbl hyperphosphorylation, leading to an increased expression of the CDKN2A transcript. In agreement with this, all tumours with CDK4 amplification and overexpression and retaining at least one CDKN2A allele, showed strong expression of CDKN2A (Table 2) .
It has to be noted that an expression study of (Arap et al, 1995) . However, as the frequency of both mutation and hypermethylation of the CDKN2A gene is low in gliomas with hemizygous deletions, the question still remains whether other gene(s) in the neighbouring region on 9p may contribute to tumorigenesis of tumours with one intact copy of CDKN2A.
The CDKN2B gene has also been proposed to be a tumoursuppressor gene. CDKN2B is included in the homo-or hemizygous deletions in all but three tumours in our series (Schmidt et al, 1994) and its protein product p15 is functionally similar to p16 (Serrano et al, 1993; Hannon and Beach, 1994) . It can also inhibit cell proliferation when ectopically expressed in glioma cell lines (Tenan et al, 1995) . However, no mutation was found in the CDKN2B gene in our present study. Only two missense mutations have been described in one study of NSCLC (Okamoto et al, 1995) and one nonsense mutation in an oesophageal cancer (Suzuki et al, 1995) . CDKN2B shows a similar expression level to CDKN2A in each tumour, suggesting common regulatory motifs. Deletion of both CDKN2A and CDKN2B may be most advantageous for progression.
Exons 2 and 3 of the CDKN2A gene have been found to be part of a novel transcript initiated from an alternative exon I (El ) Stone et al, 1995) . Recently the mouse homologue of the El transcript was found to encode a novel protein using an alternative reading frame (Quelle et al, 1995) . This protein, p1 9ARF, has the ability to induce G,-and G2-phase arrest when ectopically expressed in rodent fibroblasts. The point mutation detected in GB36 would also change an amino acid in the corresponding hypothetical human protein derived from the alternative reading frame. The human homologue of p1 9ARF may represent yet another tumour-suppressor 'gene' in this region.
In conclusion a comprehensive analysis of the CDKN2A and CDKN2B genes in primary human astrocytic tumours shows homozygous deletion to be a frequent mechanism generally resulting in the loss of both genes. Point mutations of CDKN2A and CDKN2B are infrequent events. In addition, hypermethylation of the 5' CpG island of the CDKN2A gene is rare in astrocytic gliomas.
